In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery.
about
Postjunctional α2C-adrenoceptors mediate vasoconstriction in rat tail artery: influence of precontraction and temperature on vasoreactivityNew oxadiazole derivatives showing partly antiplatelet, antithrombotic and serotonin antagonistic properties.Therapeutic potentials of sarpogrelate in cardiovascular disease.Sarpogrelate: cardiovascular and renal clinical potential.Novel fused pyrrole heterocyclic ring systems as structure analogs of LE 300: Synthesis and pharmacological evaluation as serotonin 5-HT(2A), dopamine and histamine H(1) receptor ligands.Benzophenone derivatives and related compounds as potent histamine H3-receptor antagonists and potential PET/SPECT ligands.Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300.Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers.Synthesis and dual histamine H₁ and H₂ receptor antagonist activity of cyanoguanidine derivatives.Effects of iodoproxyfan, a potent and selective histamine H3 receptor antagonist, on alpha 2 and 5-HT3 receptors.Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs.Synthesis and pharmacology of combined histamine H1-/H2-receptor antagonists containing diphenhydramine and cyproheptadine derivatives.Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.
P2860
Q28564496-42AF7A7B-C967-400D-B2AB-4E7056C7BFE1Q31150145-F781B106-1870-4121-9A6E-6A74DF3D1779Q35673144-36A1E082-A573-4F32-A303-18E211A90E46Q35814472-797E98F8-F9F4-497F-904E-17168CCA9225Q43182223-E9DEA53B-3936-45EE-BC29-FCB1FC7EA4FFQ43553879-2E403B66-1343-470D-A90B-5D5ED80FE365Q43712299-16A82CA5-CBB3-440C-9F7E-6CDB1D804BC0Q44831865-E959B99B-9327-4EF9-9BC7-340B55D6F86EQ46354241-CF5169F3-FF33-4C46-97C1-6C3B710E7514Q46680611-16054202-9220-4FC8-A87F-606D53DC6B84Q51342608-8FA7C608-2657-45C1-918D-1E3DEDD73972Q51578080-2D7DFB4E-D32F-4604-B892-366D8AA1ADD7Q53257546-7B630C73-7251-49D0-8933-CA3936A91025
P2860
In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery.
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@ast
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@en
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@nl
type
label
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@ast
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@en
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@nl
prefLabel
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@ast
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@en
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@nl
P2860
P1476
In-vitro pharmacology of sarpo ...... ntractions in rat tail artery.
@en
P2860
P304
P356
10.1111/J.2042-7158.1995.TB05801.X
P577
1995-04-01T00:00:00Z